Oragenics, Inc.OGENNYSE
Loading
R&D Expenses Over TimeContracting
Percentile Rank29
3Y CAGR-27.0%
5Y CAGR-19.4%
Year-over-Year Change
Research and development spending
3Y CAGR
-27.0%/yr
vs +31.5%/yr prior
5Y CAGR
-19.4%/yr
Recent deceleration
Acceleration
-58.5pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2024 | $4.11M | -73.4% |
| 2023 | $15.49M | +53.8% |
| 2022 | $10.07M | -4.9% |
| 2021 | $10.59M | -52.1% |
| 2020 | $22.11M | +82.4% |
| 2019 | $12.12M | +102.9% |
| 2018 | $5.97M | +68.7% |
| 2017 | $3.54M | -25.6% |
| 2016 | $4.75M | -46.0% |
| 2015 | $8.80M | - |